About admin

This author has not yet filled in any details.
So far admin has created 44 blog entries.

Sangjin Lee

2020-01-13T19:37:00+00:00

Bank of Korea Seoul National University, Economics, B.A. Sangjin Lee / Human Resources we strive to set up a proper KPI and continuously improve the foundation for fair evaluation of the passions and efforts of all colleagues in respective positions, which eventually leads to Voronoi’s culture. "Prior to joining Voronoi, I have served for the Bank of Korea over 10 years in various areas including business management, foreign exchange reserves management strategy, performance evaluation system, and macroeconomic analysis and forecast. During the time at the Bank of Korea, it was a meaningful experience to work with global investment banks in New York, USA, as I had a chance to look at how the performance-oriented and open organizational culture, which is different from the seniority-based Korean corporate organization, actually works. At Voronoi, I am responsible for establishing KPIs and organization operation. Voronoi is a young company with diverse range of professionals with outstanding careers ranging from business development, IPR, legal, strategy, patents, management support, AI, and clinical development, as well as key science areas related to new drug development such as new drugs synthesis and biotechnology. The value spectrum of each and every individual is as diverse as our specializations towards growth. With this in mind, we strive to set up a proper KPI and continuously improve the foundation for fair evaluation of the passions and efforts of all colleagues in respective positions, which eventually leads to Voronoi’s culture. " Bank of Korea Seoul National University, Economics, B.A. Sangjin Lee / Human Resources we strive to set up a proper KPI and continuously improve the foundation for fair evaluation of the passions and efforts of all colleagues in respective positions, which eventually leads to Voronoi’s culture. "Prior to joining Voronoi, I have served for the Bank of Korea over 10 years in various areas including business management, foreign exchange reserves management strategy, performance evaluation system, and macroeconomic analysis and forecast. During the time at the Bank of Korea, it was a meaningful experience to work with global investment banks in New York, USA, as I had a chance to look at how the performance-oriented and open organizational culture, which is different from the seniority-based Korean corporate organization, actually works. At Voronoi, I am responsible for establishing KPIs and organization operation. Voronoi is a young company with diverse range of professionals with outstanding careers ranging from business development, IPR, legal, strategy, patents, management support, AI, and clinical development, as well as key science areas related to new drug development such as new drugs synthesis and biotechnology. The value spectrum of each and every individual is as diverse as our specializations towards growth. With this in mind, we strive to set up a proper KPI and continuously improve the foundation for fair evaluation of the passions and efforts of all colleagues in respective positions, which eventually leads to Voronoi’s culture. "

Sangjin Lee2020-01-13T19:37:00+00:00

Gyeongmi Lee

2020-01-13T19:40:27+00:00

(Former) Boehringer Ingelheim Korea, Senior project manager, Clinical development team CHA University, Science of Nursing Gyeongmi Lee / Clinical Development I had been working as a senior project manager of clinical team in global leading pharmaceutical company. Now I am working in Voronoi and lead clinical development for our pipeline assets. "I had been working in clinical development team of global pharmaceutical companies for the last 10+ years. I was leading the management of clinical trials phase 1 to 4 to prove efficacy and safety of assets in oncology, respiratory, cardiology, etc. I was working with diverse institutions and hospitals to successfully lead the clinical trials. Based on my previous experience, I am also managing clinical trials in Voronoi to make our pipeline assets to successfully enter the clinical trial development. For successful clinical trials, I am also closely working with other teams in Voronoi and diverse hospitals and institutions in this field. In pharmaceutical industry, clinical trials are essential for effective and safe usage of drugs and through these trials, drugs can contribute to human health. Along this journey, managing clinical trials is also very important especially regarding that clinical trials require tremendous amount of money and time. For a successful new drug development, I will try my best in communicating with diverse partners including hospitals and CROs to come up with credible and valuables results of our drugs." (Former) Boehringer Ingelheim Korea, Senior project manager, Clinical development team CHA University, Science of Nursing Gyeongmi Lee / Clinical Development I had been working as a senior project manager of clinical team in global leading pharmaceutical company. Now I am working in Voronoi and lead clinical development for our pipeline assets. "I had been working in clinical development team of global pharmaceutical companies for the last 10+ years. I was leading the management of clinical trials phase 1 to 4 to prove efficacy and safety of assets in oncology, respiratory, cardiology, etc. I was working with diverse institutions and hospitals to successfully lead the clinical trials. Based on my previous experience, I am also managing clinical trials in Voronoi to make our pipeline assets to successfully enter the clinical trial development. For successful clinical trials, I am also closely working with other teams in Voronoi and diverse hospitals and institutions in this field. In pharmaceutical industry, clinical trials are essential for effective and safe usage of drugs and through these trials, drugs can contribute to human health. Along this journey, managing clinical trials is also very important especially regarding that clinical trials require tremendous amount of money and time. For a successful new drug development, I will try my best in communicating with diverse partners including hospitals and CROs to come up with credible and valuables results of our drugs."

Gyeongmi Lee2020-01-13T19:40:27+00:00

sohyun jang

2020-01-15T11:32:34+00:00

(前)Bain & Company Seoul National University Business School, B.A. (前)Bain & Company Seoul National University Business School, B.A. "I was in business development team when I first came to Voronoi and now I am in overseas IR team. I would like to describe about both works today. Voronoi is a biotech company who focuses on R&D of innovative drugs. Yes, we do make novel drugs and lead preclinical and clinical trials. Our core strategy is to license out our assets during early clinical trial phases. Business development team is in a charge of these “license out deals.” BD team keeps researching about market landscape, big pharma companies’ movements, and leads many meetings with them. BD team basically leads A to Z process for successful licensing out. Overseas IR team, as you can sense from words, leads meetings with overseas investors. There are many venture capitals and investors who are interested in investing biotech sectors. Overseas IR team leads the discussion with them. There are many interesting points about my jobs and roles. Firstly, both roles provide me with many opportunities to work with overseas counterpart and this new experience is giving me many lessons every day. Also, I handle many kinds of stakeholders from big pharma companies, to investors and venture capitals and this also gives me many lessons. See you soon in Voronoi!" "I was in business development team when I first came to Voronoi and now I am in overseas IR team. I would like to describe about both works today. Voronoi is a biotech company who focuses on R&D of innovative drugs. Yes, we do make novel drugs and lead preclinical and clinical trials. Our core strategy is to license out our assets during early clinical trial phases. Business development team is in a charge of these “license out deals.” BD team keeps researching about market landscape, big pharma companies’ movements, and leads many meetings with them. BD team basically leads A to Z process for successful licensing out. Overseas IR team, as you can sense from words, leads meetings with overseas investors. There are many venture capitals and investors who are interested in investing biotech sectors. Overseas IR team leads the discussion with them. There are many interesting points about my jobs and roles. Firstly, both roles provide me with many opportunities to work with overseas counterpart and this new experience is giving me many lessons every day. Also, I handle many kinds of stakeholders from big pharma companies, to investors and venture capitals and this also gives me many lessons. See you soon in Voronoi!"

sohyun jang2020-01-15T11:32:34+00:00

Young Mo Kang, MD, PhD

2020-01-14T15:50:49+00:00

Young Mo Kang, MD, PhD Department of Internal Medicine, Kyungpook National University School of Medicine, Korea Dr. Kang is currently professor in Kyungpook National School of Medicine, Department of Internal Medicine and Biochemistry & Cell Biology. Dr. Kang has special expertise in Rheumatology area. Dr. Kang’s educational background goes back to 1986, when he achieved his B.S. degree in Medicine in Kyungpook National University. He then achieved his PhD degree in the same school in year 1996. He then joined as an instructor in department of internal medicine in Dongguk University School of Medicine. He then became professor in Kyungpook National University, Department of Internal Medicine in 1997 and since then he is still serving his role as a professor in the same school. In 1991, he served his post-doctoral fellowship in Mayo Clinic in USA where he focused the research of Rheumatology in Department of Medicine and Immunology. Dr. Kang also served as a chairman of Department of Internal Medicine from 2014 to 2016. Dr. Kang is currently CEO of Preclina Inc. as well. Dr. Kang is currently a member of American Association of Immunologists, American Society of Matrix Biology, Asian Pacific League of Rheumatologists, Korean College of Rheumatology and an International Fellow Member of American College of Rheumatology. He has also been a steering committee of The Korean Study Group of Synovitis Research since 2007 and editor-in-chief of World Journal of Rheumatology since 2015. Dr. Kang was a principal investigator of clinical trials of Tofacitinib (Pfizer) and Filgotinib (Galapagos). Young Mo Kang, MD, PhD Department of Internal Medicine, Kyungpook National University School of Medicine, Korea Dr. Kang is currently professor in Kyungpook National School of Medicine, Department of Internal Medicine and Biochemistry & Cell Biology. Dr. Kang has special expertise in Rheumatology area. Dr. Kang’s educational background goes back to 1986, when he achieved his B.S. degree in Medicine in Kyungpook National University. He then achieved his PhD degree in the same school in year 1996. He then joined as an instructor in department of internal medicine in Dongguk University School of Medicine. He then became professor in Kyungpook National University, Department of Internal Medicine in 1997 and since then he is still serving his role as a professor in the same school. In 1991, he served his post-doctoral fellowship in Mayo Clinic in USA where he focused the research of Rheumatology in Department of Medicine and Immunology. Dr. Kang also served as a chairman of Department of Internal Medicine from 2014 to 2016. Dr. Kang is currently CEO of Preclina Inc. as well. Dr. Kang is currently a member of American Association of Immunologists, American Society of Matrix Biology, Asian Pacific League of Rheumatologists, Korean College of Rheumatology and an International Fellow Member of American College of Rheumatology. He has also been a steering committee of The Korean Study Group of Synovitis Research since 2007 and editor-in-chief of World Journal of Rheumatology since 2015.

Young Mo Kang, MD, PhD2020-01-14T15:50:49+00:00

Sunghwan Kim, PhD

2020-01-13T19:43:24+00:00

Polus, Development Director MIT, Postdoc University of Utah, Biochemistry, Ph.D Sunghwan Kim, PhD / Biochemistry Voronoi is aiming to secure research capacity and technology comparable to global pharmaceutical companies. I am responsible for whether medicines actually works as a known biological effect, which is often called drug evaluation and mechanism research. I studied microbiology in my undergraduate and acquired master’s degree in the peptide drug synthesis and protein structure. For my doctoral study, I studied the mechanism by which the HIV virus penetrates the cell and discovered a target site for an HIV virus invasion inhibitor. In addition, we proceeded with the development of therapeutics. After completing my Ph.D., I continued research in the synthesis, folding, and transport of proteins in Dr. Kaiser's laboratory, where he served as Vice President of the Department of Biology at MIT. During my post-doctoral study, I have discovered enzymes that are important for protein synthesis and folding, and revealed their biochemical and cellular biological mechanisms. Later, at UCSF's Cardiovascular Research Institute, I studied the biochemical mechanisms of receptor proteins that regulate vasodilation and contraction. After years in academia, I started the full-fledged drug development research with the development of protein-based drug candidates, expression systems and purification, and formulation development in Korea. In addition, at the Drug Development Research Center, I have participated in the development of inhibitors for various target proteins by establishing an efficacy evaluation system for synthetic drug candidates, binding analysis with target proteins, and complex structure analysis. Since then, I have led the mechanism research data, efficacy assessments, and biophysical chemical characterization at a biosimilar development company. I have established and managed an evaluation system that meets the pharmaceutical standards set forth by FDA and EMA. In the process, the USP, which is in charge of the US Pharmacopoeia, conducted verification of the new activity evaluation method for insulin drugs. As a result, we were invited to speak at the USP workshop in India this February and presented the results. Voronoi is aiming to secure research capacity and technology comparable to global pharmaceutical companies. We are forming excellent doctoral / master-level researchers and building a research system optimized for new drug development projects. We develop our methods in accordance with the ICH guidelines and obtain reliable potency levels as in global standards. In the case of new mechanism research, we are improving the degree of perfection through cooperation with all internal researchers, external advisors, and global research institutes. Polus, Development Director MIT, Postdoc University of Utah, Biochemistry, Ph.D Sunghwan Kim, PhD / Biochemistry Voronoi is aiming to secure research capacity and technology comparable to global pharmaceutical companies. I am responsible for whether medicines actually works as a known biological effect, which is often called drug evaluation and mechanism research. I studied microbiology in my undergraduate and acquired master’s degree in the peptide drug synthesis and protein structure. For my doctoral study, I

Sunghwan Kim, PhD2020-01-13T19:43:24+00:00

Jae Hee Cheon

2020-01-31T11:32:04+00:00

Jae Hee Cheon, MD, PhD Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea Dr. Cheon is currently MD in Yonsei University and he focuses in gastroenterology field. He graduated Seoul National University of Medicine in 1996 and obtained his PhD degree in 2006 at the same school. He conducted his post-graduate training in Seoul National University Hospital from 1996 to 2005. Dr. Cheon’s focus area is internal medicine and especially gastroenterology. More specifically, he has expertise in inflammatory bowel disease such as Crohn disease, Ulcerative colitis, and Behcet’s disease. Dr. Cheon received board certification in internal medicine in 2001, gastrointestinal endoscopy in 2006, gastroenterology and hepatology in 2007. He is also a current member of Institutional Review Board of Severance Hospital since 2007, Research Committee of Yonsei University since 2014, The Korean society of Gastroenterology, Hepatology, Gastrointestinal Endoscopy, etc. Dr. Cheon has received more than 20 honors and awards including the best research award in Korean FDA research and development exhibition in 2018. and best professor for referral treatment in 2014. Dr. Cheon was a principal investigator of Humira of Abbvie and Keytruda of Merck. Dr. Cheon has published more than 280+ publications over areas in intestinal disease, inflammatory bowel disease, colorectal neoplasms, etc. Jae Hee Cheon, MD, PhD Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea Dr. Cheon is currently MD in Yonsei University and he focuses in gastroenterology field. He graduated Seoul National University of Medicine in 1996 and obtained his PhD degree in 2006 at the same school. He conducted his post-graduate training in Seoul National University Hospital from 1996 to 2005. Dr. Cheon’s focus area is internal medicine and especially gastroenterology. More specifically, he has expertise in inflammatory bowel disease such as Crohn disease, Ulcerative colitis, and Behcet’s disease. Dr. Cheon received board certification in internal medicine in 2001, gastrointestinal endoscopy in 2006, gastroenterology and hepatology in 2007. He is also a current member of Institutional Review Board of Severance Hospital since 2007, Research Committee of Yonsei University since 2014, The Korean society of Gastroenterology, Hepatology, Gastrointestinal Endoscopy, etc. Dr. Cheon has received more than 20 honors and awards including the best research award in Korean FDA research and development exhibition in 2018. and best professor for referral treatment in 2014. Dr. Cheon was a principal investigator of Humira of Abbvie and Keytruda of Merck. Dr. Cheon has published more than 280+ publications over areas in intestinal disease, inflammatory bowel disease, colorectal neoplasms, etc.

Jae Hee Cheon2020-01-31T11:32:04+00:00

(Korean) 다나파버암센터, 보로노이 방문…”공동연구 강화 등 파트너십 공고화”

2019-12-30T18:57:07+00:00

Sorry, this entry is only available in Korean.

(Korean) 다나파버암센터, 보로노이 방문…”공동연구 강화 등 파트너십 공고화”2019-12-30T18:57:07+00:00

(Korean) 2019 보로노이 심포지엄 성료…국내외 의학계 별들 모였다 – 한국경제

2019-12-30T18:35:36+00:00

Sorry, this entry is only available in Korean.

(Korean) 2019 보로노이 심포지엄 성료…국내외 의학계 별들 모였다 – 한국경제2019-12-30T18:35:36+00:00